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PhysiciansAbstract Generic medicines are clinically interchangeable with original brand medicines and have
the same quality, efﬁcacy and safety proﬁles. They are, nevertheless, much cheaper in price. Thus,
while providing the same therapeutic outcomes, generic medicines lead to substantial savings for
healthcare systems. Therefore, the quality use of generic medicines is promoted in many countries.
In this paper, we reviewed the role of generic medicines in healthcare systems and the experiences of
promoting the use of generic medicines in eight selected countries, namely the United States (US),
the United Kingdom (UK), Sweden, Finland, Australia, Japan, Malaysia and Thailand. The review
showed that there are different main policies adopted to promote generic medicines such as generic
substitution in the US, generic prescribing in the UK and mandatory generic substitution in Sweden
and Finland. To effectively and successfully implement the main policy, different complementary
policies and initiatives were necessarily introduced. Barriers to generic medicine use varied between
countries from negative perceptions about generic medicines to lack of a coherent generic medicine
492 M.A. Hassali et al.policy, while facilitators included availability of information about generic medicines to both
healthcare professionals and patients, brand interchangeability guidelines, regulations that support
generic substitution by pharmacists, and incentives to both healthcare professionals and patients.
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the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/3.0/).Contents
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In recent years, many governments and third party payers have
advocated utilisation of generic medicines as a means of con-
fronting the escalation of healthcare expenditure in general
and medicine expenditure in particular, by instigating various
policies, initiatives and strategies (Simoens and De Coster,
2006; Sermet et al., 2010; Godman et al., 2010a; Godman
et al., 2012a; Ministry of Health Labour and Welfare of Japan,
2012a; Godman et al., 2012b). A generic medicine is deﬁned by
the World Health Organization (WHO) as ‘‘a pharmaceutical
product, usually intended to be interchangeable with an inno-
vator product that is manufactured without a licence from the
innovator company and marketed after the expiry date of the
patent or other exclusive rights’’ (WHO, 2012). A generic med-
icine is identical to its corresponding innovator medicine in
terms of safety, quality, efﬁcacy, dosage form, strength and
route of administration, and has the same intended use as
the innovator medicine (The US Food and Drug Administra-
tion (FDA), 2009). The active ingredients are the same but the
excipients (i.e. inactive ingredients) might differ from oneproduct to another (US FDA, 2012) as some other aspects
including shape, colour and packaging (U.S. Department of
Health and Human Services, FDA/CDER, 2012).2. Objective of the review
This paper aimed to highlight the vital roles of generic medi-
cines in healthcare systems and the need to establish and imple-
ment generic medicine policies. In this review, the experiences
of promoting the use of generic medicines were explored in
eight selected countries, namely the United States (US), the
United Kingdom (UK), Sweden, Finland, Australia, Japan,
Malaysia and Thailand. As it will be shown later in this review,
the policies adopted are different from one country to another.
For example, generic substitution is encouraged in the US,
while it is legally not allowed in the UK and mandatory in
the Sweden. Thus, due to these signiﬁcant differences, direct
comparison between countries was not attempted but rather
the experience of each country was presented narratively with
more focus on main policies. After that, by analysing the
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promotion and implementation of generic medicines including
main facilitators that helped to increase the use of medicines
and also barriers that hindered generic substitution were pre-
sented in the form of general recommendations that would
be valuable to policy makers to consider when implementing
or improving the current generic medicine.
3. Methodology
The country experience of promoting generic medicines was re-
viewed in eight selected countries. The selection was based on
several factors. The US was selected because generic substitu-
tion is a very common practice while the UK was selected be-
cause generic prescribing is a standard practice. Two European
countries, namely Finland and Sweden were also selected be-
cause they have successfully implemented mandatory generic
substitution policy. In the Asia Paciﬁc region, Australia, Ja-
pan, Malaysia and Thailand were selected. In Australia and
Japan, several policies related to generic medicines are applied,
thus their experiences would be useful. The situation in Malay-
sia and Thailand where no coherent generic medicines policy
are in place was also explored. This narrative review was based
on an extensive literature search using several electronic dat-
abases and search engines including PubMed, Medline, ISI
Web of Knowledge, Scopus, Science Direct, Springer Link,
Proquest, Ebsco Host, Google Scholar and Google. Addi-
tional articles and sources were identiﬁed by reviewing the bib-
liography of the retrieved articles. In addition, websites of
several organisations and agencies including drug regulatory
authorities in the reviewed countries were visited for relevant
information and reports. The search strategy involved using
Boolean operators for combinations of several key words
including generic medicine, brand medicine, innovator medi-
cine, generic dispensing, generic prescribing, generic substitu-
tion, generic medicine policy, medicine expenditure, medicine
pricing, names of the reviewed countries (e.g. Japan), pharma-
cists, physicians, practitioners, prescribers and patients. Equiv-
alent terms in thesauruses or Medical Subject Heading
(MeSH) browsers were used whenever possible.
4. Role of generic medicines in healthcare system
4.1. Affordability and Access to medicines
The WHO estimated that at least 30% of the world’s popula-
tion lacks regular access to essential medicines, and the ﬁgure
increases to 50% in the poorest countries of Africa and Asia
(WHO, 2011). One of the most important barriers to access
to medicines is their high cost (Cameron et al., 2009; Huskamp
et al., 2003). Medicine prices are often unaffordable not only
for large sectors of the population in low- and middle-income
countries, but also for sizeable segments of the population
without adequate social protection or insurance in high income
nations (Organisation for Economic Co-operation and Devel-
opment (OECD), 2008; Cameron et al., 2009). Given that gen-
eric medicines are 20–90% cheaper than their counterpart
innovator brands (Matin, 1999; Shaﬁe and Hassali, 2008)
and ‘‘gold standard’’ and ‘‘ﬁrst-line therapy’’ for many acute
and chronic diseases (Sheppard, 2011), promoting generic
medicines is important to improve medicine access both forgovernments and individuals who have to pay out of pocket
for medicines (Cameron et al., 2009). Furthermore, generic
medicines are not only cheaper substitutes for innovator
medicines, they also play a role in lowering the prices of
off-patent innovator medicines and other generic equivalents.
A study in the US found that while the price of a ﬁrst entry
generic medicine was only marginally lower than the innovator
brand price, the entry of a second generic medicine dropped
the average generic price to about 50% of the innovator brand
price. When a large number of generic medicines entered the
market, the average generic price fell to 20% or even lower
(US FDA, 2010). The introduction of mandatory generic
substitution policy in Sweden resulted in a 15% reduction in
overall medicine prices and more than 40% decrease in
prices of off-patent medicines within 4 years of the policy
implementation (Pharmaceutical Beneﬁts Board (LFN),
2007). Similar results were found in Finland, with a 10.6%
reduction in substitutable medicine prices and up to 80% price
decrease for some medicines during the ﬁrst year of mandatory
generic substitution policy implementation (Aalto-Seta¨la¨,
2008).
4.2. Effective cost containment strategy
Given the limited resources, increasing health expenditure due
to growing healthcare demand is a challenge faced by most
countries around the world. Medicine spending often ac-
counts for a large part of the total health expenditure, ranging
from 20% to 60% in middle- and low-income countries
(WHO, 2004). Moreover, it has been steadily rising as one
of the most rapidly growing components of healthcare expen-
ditures (Henriksson et al., 1999; Schneeweiss et al., 2002; Ess
et al., 2003; Zuvekas and Cohen, 2007; Wettermark et al.,
2008; Saudi Ministry of Health (MOH), 2008; Godman
et al., 2009; Coma et al., 2009; Sermet et al., 2010; Godman
et al., 2010a; Godman et al., 2010b; Leng et al., 2011;
Hoffman et al., 2012). Therefore, containing medicine expen-
diture is necessary prior to overall health expenditure
containment.
Generic medicines offer a great opportunity for substantial
savings, being 20–90% cheaper than their counterpart innova-
tor medicines (Matin, 1999; Shaﬁe and Hassali, 2008). In the
US, generic medicines saved the healthcare system about one
trillion dollars over 10 years from 2002 to 2011 (Generic Phar-
maceutical Association, 2012). Switching procurement from
innovator brands to the lowest priced generic equivalents in
the private sector in 17 developing countries could result in
an average of 60% cost savings (Cameron et al., 2012). Mak-
ing this switch for only four medicines in the public sector in
China could potentially save US $ 370 million (Cameron
et al., 2012). In Europe, generic medicines accounted for more
than 50% of market share in volume but only 18% in value
(Sheppard, 2011). Therefore, generic prescribing and generic
substitution are often promoted as strategies for containing
the escalating cost of the medicines.4.3. Generic medicine policy as part of the national medicine
policy
According to theWHO, the national medicine policy is ‘‘a com-
mitment to a goal and a guide for action’’ with an objective of
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pharmaceutical sectors. In addition, it should ensure not only
the availability and accessibility to high quality, safe and effec-
tive medicines, but also promote cost effective use of medicines
to healthcare professionals and consumers (WHO, 2003). Pro-
motion of generic medicines is recommended to be included as
part of the national medicine policy (Cameron et al., 2012) as
it helped to achieve a comprehensive and sustainable healthcare
system in Europe (Godman et al., 2010a). This is needed to im-
prove the affordability, and thus accessibility of medicines in
developing countries (Cameron et al., 2009).
5. Country experiences with generic medicines
5.1. The United States of America
In the US, total medicine expenditure has steadily increased
and reached $ 326 billion in 2012. Nevertheless, widespread
use of generic medicines in recent years helped to slow the
growth of medicine expenditure (Hoffman et al., 2012, 2013).
It is estimated that about 80% of prescriptions ﬁlled are gen-
eric medicines (US FDA, 2012). Generic substitution (GS) is
a common practice in the US, and pharmacists play an essen-
tial role in promoting generic medicines as they substituted
83.8% of prescriptions that allowed substitution (Mott and
Cline, 2002). Several factors have led to this phenomenon,
one being that GS is addressed and regulated by all states.
However, GS regulations may differ from one state to another
in many respects (Assistant Secretary for Planning and Evalu-
ation (ASPE), 2013, U.S. Department of Health and Human
Services; Bobinmyer-Hornecker, 2011; Vivian, 2008). The ﬁrst
issue to be addressed is which medicines to substitute. Some
states adopt positive formulary concept (i.e. a list of substitut-
able generic medicines), while others adopt negative formulary
(i.e. generic medicines that should not be substituted). More-
over, the issue of Narrow Therapeutic Index (NTI) medicines
is considered (ASPE, U.S. Department of Health and Human
Services; Bobinmyer-Hornecker, 2011; Vivian, 2008). The sec-
ond to be addressed is generic substitution by pharmacists.
According to some state laws, pharmacists are required to sub-
stitute brand medicine with its therapeutic equivalent generic
version unless prohibited by the prescriber (i.e. mandatory
GS), while in some states GS is just allowed (indicative/permis-
sive GS) (ASPE, U.S. Department of Health and Human Ser-
vices; Anonymous (epilepsy.com), 2007), and some others
require pharmacists to obtain patients’ consent before GS
(ASPE, U.S. Department of Health and Human Services).
However, while it seems there is no apparent impact of the
status of GS (i.e. mandatory vs. indicative) on the rate of
GS, obtaining consent from patients was associated with a
lower GS rate (lower by 25%) in states that impose obtaining
consent compared with those that do not require it (Shrank
et al., 2010). This could be explained in part by the fact that
many patients prefer to use branded medicines over generic
medicines (Keenum et al., 2012; Shrank et al., 2009). Thus,
GS laws have an impact on GS (ASPE, U.S. Department of
Health and Human Services; Shrank et al., 2010).
Another factor is that patients are encouraged to use gener-
ic medicines by making them pay signiﬁcantly less co-payment
when selecting generic medicines as most pharmacy plans
and designs and insurers adopted formularies with three tierco-payment. In this system or plan, patients pay the lowest
co-payment for generic medicines (ﬁrst tier), a middle co-
payment for preferred brand name medicine (second tier)
and the highest co-payment for the expensive non-preferred
brand name medicine (third tier) (Huskamp et al., 2003; Kohl
and Shrank, 2007; Shrank et al., 2006, 2007; Congressional
Budget Ofﬁce (CBO) Congress Of The United States, 2010).
For example, in 2009, in Stand-alone prescription-drug plan,
average co-payment for generic medicines was USD $ 7, while
for preferred brand medicines and non-preferred brand medi-
cines, it was USD $ 37 and $ 75 respectively (Neuman and
Cubanski, 2009). Another approach to encourage generic med-
icines is the step therapy concept, which is use of a cheaper
generic medicine or preferred brand medicine before using a
more expensive brand medicine. In addition, to prescribe some
expensive medicines when an equivalent generic version is
available, pre authorisation is required (Congressional Budget
Ofﬁce (CBO) Congress Of The United States, 2010).
At the federal level, the approved drug products and thera-
peutically equivalent generic medicines are listed in the orange
book, which is a useful guide for pharmacists and other health-
care professionals as regards therapeutic equivalence and ap-
proved generic medicines in the US (U.S. Department of
Health and Human Services-FDA/CDER, 2012). However,
as pharmacy practice law regarding generic substitution varies
between states, pharmacists are required to be familiar with
and perform product substitution in accordance with the indi-
vidual state’s Pharmacy Practice Act (Bobinmyer-Hornecker,
2011; Vivian, 2008). Pharmacists are playing an essential role,
therefore, any policy should make sure their incentives to dis-
pense generic medicines are maintained (Coster, 2010, 2012).
On the other hand, generic prescribing is still not common
practice in the US (Steinman et al., 2007). Furthermore, many
physicians have negative perceptions about generic medicines
and lack in-depth knowledge about the bioequivalence concept
applied in the US (Shrank et al., 2011). Also, the US FDA, be-
sides ensuring quality, safety and efﬁcacy of generic medicines
via a rigorous registration process, makes efforts to promote
generic medicines by educating both consumers and healthcare
professionals to increase their conﬁdence in generic medicines
(US FDA, 2009; US FDA, 2012). Promotion of generic med-
icines in the US resulted in substantial savings (about one tril-
lion US dollars) over one decade (Generic Pharmaceutical
Association, 2012).
5.2. The United Kingdom
Unlike the US, generic prescribing is a more common practice
in the United Kingdom (UK). In 2008, more than 83% of pre-
scriptions in general practices were written for generic names
(Department of Health, 2009b). In addition, generic substitu-
tion is a common practice in NHS hospitals (Duerden and
Hughes, 2010; Ferner et al., 2010). However, as generic pre-
scribing is a standard practice, GS is not allowed in the pri-
mary care setting and community pharmacists are required
to dispense the prescribed brand (Department of Health,
2009a). Several factors have led to this practice. In fact, INN
prescribing is encouraged at early stages as medical schools
in the UK are teaching medical students generic prescribing
(Simoens and Coster, 2006; Simoens and De Coster, 2006;
Duerden and Hughes, 2010). Another factor is that physicians
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ﬁnancial incentives, to prescribe generically. Financial incen-
tives include, for example, physicians’ budgets and budgetary
incentives, generic prescribing targets with incentives. In bud-
getary incentives, savings achieved by the physicians beyond
the indicative budget can be used for other purposes such as
training. Other factors include empowering physicians with
technology and decision support systems to help them pre-
scribe generically (such as generic prescribing programmes),
and providing them with information via national and local
cost effective prescribing guidelines (e.g. NICE guidelines).
In addition, prescribing monitoring and feedback to improve
physicians’ prescribing and awareness of medicines costs is
also used to encourage generic prescribing (The association
of the British Pharmaceutical Industry (ABPI), 2013; Simoens
and Coster, 2006; Simoens and De Coster, 2006; Habl et al.,
2006; Sturm et al., 2007; Bongers and Carradinha, 2009;
Vogler and Schmickl, 2010).
For prescriptions written by INN, pharmacists dispense
generic medicines because the Drug Tariff Price (i.e. reim-
bursement level price) is usually set well below the price of
the brand medicine (Simoens and Coster, 2006). Therefore,
to make pharmacists dispense their generic product, generic
medicine manufacturers and wholesalers offer substantial dis-
counts on the reimbursement price, which exceed 60% – or
even 80% – for some medicines (Kanavos, 2007). However,
the practice or competition which arises by providing dis-
counts while the reimbursement price is ﬁxed (i.e. the retail
price is not reduced), means the payers (i.e. NIH) do not re-
ceive the beneﬁt of substantial savings that could be achieved
by generic medicines as they are paying more than the actual
price of the generic medicines (Dylst and Simoens, 2010;
Kanavos, 2007; Simoens, 2012). To address this issue, there-
fore, Manufacturers ‘‘M’’ and Wholesalers ‘‘W’’ schemes were
introduced in 2005. In these voluntary schemes, net discounts
need to be disclosed so that the reimbursed level reﬂects the
prices after discounts (Department of Health, 2005a,b, 2010).
As a result, the prices of generic medicines were reduced by
32.4% in 2005 (Ofﬁce of Fair Trading (OFT), 2007) and
overall prices of medicines by 2% one year after the schemes’
introduction (Godman et al., 2012c). It is also noted that
although patients are given information about generic
medicines, there are no incentives for them to accept generic
medicines (Simoens and Coster, 2006).
Thus, physicians play an essential role especially in general
practices in the UK by prescribing generically as community
pharmacists are not allowed to perform GS. Therefore, adop-
tion of cost effective prescribing (i.e. prescribing cheaper gen-
eric medicines) by GPs in England resulted in cost saving of
around US $ 600 million in 2008 (Coombes, 2009). In the
UK, British National Formulary (BNF) recommendations
are a useful source for healthcare professionals when GS is
not suitable for some medicines (Duerden and Hughes, 2010;
Ferner et al., 2010; Joint Formulary Committee, 2011).
5.3. Finland
Generic substitution was introduced for the ﬁrst time in Fin-
land in 1993, then it was stopped in 1996 and replaced by gen-
eric prescribing (Martikainen and Rajaniemi, 2002). Since
2003, generic substitution has been mandatory. In this policy,the pharmacist has to substitute the prescribed medicine with
the cheapest interchangeable product or close to the cheapest
product (i.e. the product to be offered should be within a spe-
ciﬁc price range, also known as the price corridor/band). How-
ever, consumers can refuse GS and physicians also can forbid
its use (Aalto-Seta¨la¨, 2008; Heikkila¨ et al., 2007). When asked
their opinions about generic substitution during the ﬁrst year
of mandatory GS, consumers spoke of different reasons for
accepting GS, including saving money and encouragement
from pharmacists through their advice and recommendations.
Some consumers refused GS because they were comfortable
with the medicines they were using or confused and uncertain
about GS (Heikkila¨ et al., 2007). Physicians generally accepted
GS policy, but some believed that certain interchangeable gen-
eric products are not of the same effectiveness and safety pro-
ﬁle (Heikkila¨ et al., 2007). To facilitate properly GS, the
Finnish Medicines Agency (Fimea) quarterly issues a list of
interchangeable products that can be substituted (Heikkila¨
et al., 2007; The Finnish Medicines Agency (Fimea), 2013).
GS substitution leads to cost saving directly by substituting
the expensive brands and reducing the price of medicines due
to competition. This is because drug companies have to reduce
their price to be in the price corridor/band if their products are
to be substituted by pharmacists (Aalto-Seta¨la¨, 2008; The
Social Insurance Institution of Finland (KELA), 2009).
5.4. Sweden
Sweden has introduced mandatory generic substitution since
2002. In this system, community pharmacies are obliged to dis-
pense the least expensive generic medicine or parallel imported
medicine available in the pharmacy. However, prescribers can
disallow GS. Patients can also refuse GS but they are required
to pay the price difference between the generic and the more
expensive brand medicine (Pharmaceutical Beneﬁts Board
(LFN), 2007). Andersson et al. (Andersson et al., 2005) evalu-
ated the barriers to implementation of GS and the cost saving
achieved during the ﬁrst year. The study concluded that the
majority of prescribers and patients accepted GS. However,
patients declined GS when the price difference was not signif-
icant. The actual saving resulting from substituting six medi-
cines was SEK 15.6 million, which represented 60% of the
total possible savings. Additional savings, therefore, can be
achieved by GS and probably by introducing generic prescrib-
ing (Andersson et al., 2005). GS introduction also led to a drop
in medicine prices (LFN, 2007) and decreased the growth of
the medicine expenditure (Andersson et al., 2007). In Sweden,
the Swedish Medical Products Agency (MPA) produces a list
of therapeutically interchangeable products to guide the
process of GS (Andersson et al., 2005; The Swedish Medical
Products Agency (MPA), 2010).
5.5. Australia
The pharmaceutical beneﬁt scheme (PBS), as an essential com-
ponent of the Australian healthcare system, which has been in
operation since 1948, aims to ensure ‘timely access to the med-
icines that Australians need, at a cost individuals and the com-
munity can afford’. Under this scheme, the cost of PBS listed
prescription medicines is subsidised by the government
(Department of Health and Aging). However, the patients
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prescriptions (Department of Health and Aging; Department
of Health and Aging, 2013). In 1 year (July 2011 to June
2012), the total volume of PBS prescriptions was 194.9 million
and the total expenditure was AUD 9, 193.7 million. The gov-
ernment expenditure represented 83.4% of PBS prescriptions’
total cost and the rest was paid by patients’ contributions (PBS
Information Management Section, 2012).
Reference pricing (RP) system is a key feature of the PBS,
which opens up space for generic medicines (Beecroft, 2007;
Lofgren, 2004; Lofgren, 2009). In 1990, the Brand Premium
Policy was introduced. This policy, using reference pricing
principle, is applied when there is more than one brand of
the identical medicines listed, and these are off-patent medi-
cines and generic equivalents. In this system, the government
subsidises all equivalent medicines by a ﬁxed reimbursement/
subsidy level, which is equivalent to the lowest priced brand
(known as benchmark price). The companies can set their price
higher than the benchmark, but the patients have to pay the
brand premium, which is the difference between the actual
price of the medicine and the benchmark (Department of
Health and Aging; Beecroft, 2007; Department of Health
and Aging, 2013; Lofgren, 2004, 2009). In 1994, pharmacists
were allowed to perform GS for products listed on the PBS
schedule if they had patient consent and no objection from
the prescriber (Beecroft, 2007). In 1998, the Therapeutic
Group Premium (TGP) Policy was introduced. In this policy,
government subsidises all medicines in a speciﬁc therapeutic
group, which are deemed to have similar safety, efﬁcacy pro-
ﬁles and health and therapeutic outcomes to the level of the
lowest priced medicine. The companies can set the price of
their medicines higher than that of the lowest priced medicines,
but the patients have to pay the therapeutic group premium,
which is the difference between the actual price and the subsi-
dised price (Department of Health and Aging; Beecroft, 2007;
Department of Health and Aging, 2013; Lofgren, 2004, 2009).
However, as the medicine suppliers can set their prices, they
usually price them close to the original medicines (Lofgren,
2004). At the same time, they offer substantial discounts (up
to 50% in some cases) to community pharmacies to dispense
their products preferentially (Beecroft, 2007; Lofgren, 2004,
2009). Moreover, some physicians especially in the private
sector did not support GS, which they disallowed in their pre-
scriptions probably due to lack of incentives when prescribing
generic medicines (Lofgren, 2004). Therefore, this not only
raised the prices of generic medicines (Bulfone, 2009) and low-
ered utilisation (Lofgren, 2004; Organisation for Economic
Co-operation and Development (OECD), 2008), it also meant
that the government did not get the value of generic medicines
as the reimbursement level was much higher than the actual
price of the generic medicines. Thus, despite the introduction
of these policies, the escalating cost of the PBS is challenging
the sustainability of this scheme. For example, for over
10 years (1995/96 – 2004/05), the cost of PBS was annually
increasing by around 13%. In addition, the prices of generic
medicines are high compared with those in other OECD
countries (Bulfone, 2009; OECD, 2008).
Therefore, in 2005, a mandatory 12.5% price reduction pol-
icy was introduced. According to this policy, to be listed on the
PBS, the ﬁrst new generic version of a medicine already on the
PBS must be priced at least 12.5% below the current lowest
priced brand. Under the reference pricing, the presence of anew, cheaper generic brand in the group would reduce the
group price benchmark and the price cut would affect all the
medicine brands (Beecroft, 2007; Lofgren, 2009). Furthermore,
comprehensive changes to the pricing system and mechanism
of pricing, which included mandatory price reduction and
price disclosure, were introduced in late 2006 (Department of
Health and Aging, 2007; Lofgren, 2009). As a result of these
changes, for the purpose of pricing, the PBS medicines were
separated into two formularies. Formulary 1 (F1) contains sin-
gle brand medicines (almost all medicines in this formulary are
patented medicines). Formulary 2 (F2) includes multiple brand
medicines and single brand medicines in a therapeutic group
with a medicine or medicines that have multiple brands. The
medicines in the therapeutic group should be of similar safety
and efﬁcacy proﬁles and therapeutically interchangeable. ACE
inhibitors and Proton Pump Inhibitors are examples for such
therapeutic groups (Department of Health and Aging, 2007).
In this system, there are no price links between medicines listed
on F1 and medicines listed on F2. However, the reference pric-
ing system is applied in each formulary. For F1 medicines,
Therapeutic Group Premium (TGP) policy is applied to med-
icines that are linked within a speciﬁc therapeutic group. For
medicines listed on F2, Therapeutic Group Premium (TGP)
policy and brand premium policy are applied whenever rele-
vant (Department of Health and Aging, 2007; Lofgren,
2009). Medicine prices are required to be disclosed to ensure
that government payments reﬂect the actual price of the med-
icine. In addition, mandatory price reductions are applied on
all medicines listed on F2. For price cut, F2 was divided into
two sub-formularies (F2A and F2T) depending on trading
terms (i.e. discounts that community pharmacies get from drug
companies and suppliers when purchasing their medicines).
F2A contains medicines that have less than 25% discount
and F2T contains medicines that have 25% discounts or more.
Prices were cut by 2% per year for 3 years (2008, 2009 and
2010) for medicines listed on F2A and a one off 25% cut (in
2008) for medicines listed on F2T. The 12.5% price reduction
policy is ongoing and will come into force whenever it is appli-
cable (Department of Health and Aging, 2007; Lofgren, 2009).
Moreover, since August 2008, to encourage pharmacists to dis-
pense cheaper brands, they are paid, as an incentive, when they
dispense a substitutable, premium-free PBS medicine. This
incentive payment is known as premium free dispensing incen-
tive and equal to AUD 1.50 as of August 2010 (Department of
Health and Aging, 2007; Department of Human services,
2012).
It was estimated that around 34.7% of PBS prescriptions
were ﬁlled with generic medicines in 2008, representing around
17.6% of the PBS prescription costs (in 2001, this was esti-
mated at around 19.2%). The Centre for Strategic Economic
Studies (CSES) estimated that over 10 years, 2008/09 – 2017/
18, as a result of the comprehensive reforms introduced in
2006, the Australian system will save $6.4 billion (The Centre
for Strategic Economic Studies (CSES), 2009). In Australia,
the schedule of pharmaceutical beneﬁt is a very useful guidance
for healthcare professionals and consumers as regards thera-
peutic equivalence between medicines, prices of medicines,
brands subjects to brand premium and Therapeutic group pre-
miums (Department of Health and Aging, 2013). In addition,
National Prescribing Service limited (NPS), an independent
not-for-proﬁt organisation, plays a pivotal role in educating
consumers about generic medicines and brand choices, as well
The experiences of implementing generic medicine policy in eight countries 497as organising educational campaigns and educational materi-
als. NPS is also a good source for healthcare professionals
(National Prescribing Service Limited (NPS), 2012).
5.6. Japan
The Japanese national health expenditure increased from
about 30.1 trillion Yen in 2000 to 36 trillion Yen in 2009.
The medicine component represented approximately 22.2%
of the total health expenditure (Ministry of Health Labour
and Welfare of Japan (MHLW), 2012b). Generic medicine
utilisation in the Japanese healthcare system is low. In 2005,
the volume of generic medicines was 16.8% and increased to
22.8% of the market volume in September 2011 (MHLW,
2012a). Currently, the government aims to achieve a generic
market share of more than 30% by early 2013 (MHLW,
2012a). Therefore, to promote generic medicine utilisation,
generic medicine policies have been introduced since 2002. Dif-
ferent policies were introduced including those to speed up reg-
istration on the reimbursement list, to provide ﬁnancial
incentives to encourage physicians to prescribe and pharma-
cists to dispense generic medicines and generic substitution
policy (Iizuka, 2009; Simoens, 2009).
Prior to being reimbursed from health insurance, prescrip-
tion medicines must be registered to the Ministry of Health,
Labour and Welfare (MHLW) to be on the ofﬁcial list of pre-
scription medicines with an assigned reimbursement price (Ii-
zuka, 2009). Since 2007, to speed up the registration of
generic medicines on the reimbursement list, generic medicines
can be registered twice a year rather than once a year as previ-
ously (Simoens, 2009; Kobayashi et al., 2011b). In addition,
since 2004, the prices of generic medicines on the reimburse-
ment list have to be at least 30% cheaper than the originator
medicines (Simoens, 2009; et al., 2011b).
Generic substitution policy was introduced for the ﬁrst time
in 2006. Consequently, pharmacists were only able to substi-
tute with permission from prescribers (Simoens, 2009). How-
ever, since 2008, GS policy has been changed. Pharmacists
can perform GS unless the physicians prohibit it (Iizuka,
2009; Kobayashi et al., 2011a; Simoens, 2009). GS is encour-
aged because it is estimated that successful implementation
of GS policy would result in a saving of about Japanese Yen
(JPY) 1.3 trillion of the total annual medicine expenditure
(Ministry of Finance of Japan). To enhance further generic
medicine utilisation, ﬁnancial incentives for physicians, phar-
macists and hospitals were also introduced. Physicians are
incentivised by JPY 20 when they prescribe a generic medicine
or prescribe a medicine by generic (INN) name. Pharmacists
are also given JPY 170 if the share of generic medicines in their
pharmacies is over 30% in a three-month period. In addition,
to encourage pharmacists to educate consumers and patients
about generic medicines, they are entitled to JPY 100 when
they provide patients with information about generic medi-
cines (Kobayashi et al., 2011b; Simoens, 2009).
Despite all these policies and initiatives, generic medicine
utilisation is still low. The barriers identiﬁed include unstable
supply of generic medicines to the market and factors related
to healthcare professionals (i.e. physicians and pharmacists)
(Iizuka, 2009; Kobayashi et al., 2011b; MHLW, 2012a). The
former was addressed in 2007, when the Japanese Ministry
of Health, Labour and Welfare requested from genericmedicine manufacturers that they ensure a stable, nationwide
supply for price-listed medicines for at least ﬁve years (Simo-
ens, 2009). The latter was more entrenched due to a number
of reasons. The low acceptance from prescribers was because
of negative perceptions about generic medicines (Iizuka,
2009; MHLW, 2012a). Many pharmacists ‘‘seldom or never
recommend’’ GS to patients as a result of the unavailability
of generic medicines in the pharmacy stock, patients’ objection
due to insigniﬁcant cost saving, objection by physicians,
doubts about the quality of generic medicines and insufﬁcient
information about generic medicines (Kobayashi et al., 2011b).
Furthermore, patients lack knowledge about the availability of
generic medicines and are not aware of generic substitution at
community pharmacies (Kobayashi et al., 2011a). Implemen-
tation of a more comprehensive educational campaign to im-
prove further public perception about generic medicines is
therefore needed (Kobayashi et al., 2011a).
5.7. Malaysia
In 1999, the Drug Control Authority (DCA) of the Malaysian
Ministry of Health reviewed the registration process of generic
medicines to ensure the best international standards and prac-
tices were applied. Consequently, bioequivalence studies have
become an essential requirement in registering generic medi-
cines, except for a few generic products which have bioequiv-
alence studies waived when scientiﬁcally appropriate (Centre
For Product Registration, 2013; National Pharmaceutical
Control Bureau (NPCB), 2013; Ministry of Health Malaysia;
NPCB, Ministry of Health Malaysia; NPCB, Ministry of
Health Malaysia, 2013). Notwithstanding the efforts of na-
tional authorities, there are still misconceptions and negative
perceptions about generic medicines in terms of quality, efﬁ-
cacy, safety and bioequivalence among physicians, pharma-
cists and patients (Al Gedadi et al., 2008; Chua et al., 2010;
Chong et al., 2011a; Hassali et al., 2012; Thomas and Vitry,
2009). The reasons might be a lack of a comprehensive generic
medicine policy as well as guidelines that govern GS in Malay-
sia (Chong et al., 2011b). As a result, originator medicines are
actively dispensed by community pharmacists even for chronic
diseases when equivalent cheaper generic medicines are avail-
able (Babar and Awaisu, 2008).
To address the problem, a GS policy is being considered for
future implementation (Ministry of Health Malaysia, 2009),
which is supported by community pharmacists (Chong et al.,
2010), although the majority prefer a voluntary GS to compul-
sory GS (Babar and Awaisu, 2008). The feasibility of policy
implementation further increases as patients generally accept
the offer of GS by community pharmacists (Chong et al.,
2011b). However, to improve acceptance and utilisation of
generic medicines consumers need to be educated about gener-
ic medicines to gain sufﬁcient knowledge and eliminate nega-
tive perceptions (Al Gedadi et al., 2008; Thomas and Vitry,
2009). Generic medicines passing bioequivalence tests are cur-
rently listed on the ‘‘generic product list for bioequivalence
studies’’, which is disseminated and published online for easy
access to healthcare professionals (National Pharmaceutical
Control Bureau (NPCB). Ministry of Health Malaysia). How-
ever, a formulary of therapeutically interchangeable products
is still needed to guide generic substitution (Chong et al.,
2010; Chua et al., 2010).
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prices in the private sector are not regulated by government
(Hassali et al., 2010; Shaﬁe and Hassali, 2008). Therefore,
medicine prices are determined by the market force (Babar
et al., 2007). Nevertheless, the generic medicines in Malaysia
are much cheaper than original brand medicines as it is esti-
mated that original brand medicines are 27–90% more expen-
sive than generic medicines (Shaﬁe and Hassali, 2008). Thus,
GS can lead to substantial cost savings for both community
pharmacies and medicine consumers. It is estimated that GS
can save around 70% of the cost in stock purchasing for com-
munity pharmacists and approximately 60% of patients’
spending on medicines (Chong et al., 2011b; Ping et al., 2008).
5.8. Thailand
In Thailand, around 97.4 % of the population was covered by
insurance in 2009. Currently, there are three major insurance
schemes, namely, Universal Coverage of Healthcare (UC)
Scheme (introduced in 2002 and currently approximately 74%
of the population are covered by this scheme), Civil Servant
Medical Beneﬁt Scheme (CSMBS) and the Social Security
scheme (SSS) (Bureau of Policy and Strategy.Ministry of Public
Health of Thailand). In Thailand, total Healthcare expenditure
was approximately baht 588,154 million in 2008 (1 US$ = 33
baht in 2008). The total pharmaceutical expenditure repre-
sented approximately 34.16% in 2000 and steadily increased
to 46.4% of the total health expenditure in 2008. Government
expenditure on health represented 42.23% of the total health
expenditure in 2008. (Bureau of Policy and Strategy Ministry
of Public Health of Thailand, 2008–2010). In Thailand, out of
pocket payment represented approximately 57.6% of private
health expenditure in 2008 (Bureau of Policy and Strategy
Ministry of Public Health of Thailand, 2008–2010).
At present, there is no policy that regulates the prices of
medicines in the private and public sectors in Thailand. More-
over, similar to many other developing and middle income
countries (Cameron et al., 2009), both brand medicines and
generic medicines are sold at higher prices compared with
international reference prices. This could be in part explained
by lack of price control and high mark-ups. In the public sec-
tor, for example, mark-up ranges for original medicines and
generic medicines were 28–41% and 20–285% respectively.
However, generic medicines are much cheaper than original
brand medicines. For example, in the private sector, original
medicines are more expensive than generic medicines by about
3.9 times (World Health Organization/Health Action Interna-
tional (WHO/HAI), 2006; Cha-oncin et al., 2009). Therefore, it
is necessary to consider a pricing system implementation and
to review medicine prices.
In Thailand, GS policy is adopted in some insurance pro-
grammes (WHO/HAI, 2011). In addition, some hospitals have
recently introduced mandatory generic substitution in inpa-
tient settings. The evaluation of this policy reported that it
would yield a signiﬁcant cost saving if extended to include
other settings (i.e. outpatient settings) (Kaojarern and Patta-
naprateep, 2012). In addition, nationwide promotion of GS
could yield a substantial cost saving to the healthcare system.
For example, average potential savings for seven medicines
that could be achieved from using lowest generic medicines in-
stead of original brand medicines were 76 ± 13% equivalent
to USD 3,997,118 (Cameron et al., 2012).In Thailand, it seems that generic prescribing in primary
care practice is common. However, there is still scope for
improvement in this regard (Plianbangchang et al., 2010).
Moreover, most surveyed pharmacists in the study conducted
by Sukontharat et al. (Sukontharat et al. 2012) showed that
pharmacists are supportive of GS policy implementation.
However, they stated that before implementation of generic
policy, arrangement and agreement between other healthcare
professionals are important.
6. Lessons learned and recommendations to improve generic
medicine use
In general, to effectively promote generic medicines, it is evi-
dent that any main policy to promote generic medicines needs
to be supported by some complementary policies to facilitate
its implementation or to overcome the barriers that may hinder
its effective implementation. This is consistent with the ﬁndings
that have been reported by Simoens (2010) in Europe (Simoens,
2010). From reviewing the generic medicine experiences in the
eight countries, the following recommendations can be made.
6.1. National drug authorities
Generic medicines should be registered via a rigorous scientiﬁc
based registration system to ensure the quality, safety, efﬁcacy
and bioequivalence of generic medicines. In addition, a post-
marketing follow-up and monitoring system should be in place
to detect any safety or quality issues that may arise after reg-
istration. Furthermore, it is of great importance that medicine
registration authorities communicate with healthcare profes-
sionals and consumers to make them aware of the registration
system requirements and the standards that medicines must
pass through before being granted approval. This will make
them conﬁdent in the generic medicines as essentially the same
as the original brand medicines and that all medicines go
through the same registration process. Moreover, drug regula-
tory authorities should ensure that only quality products are
available in the market, because availability of low quality or
counterfeit medicines not only makes prescribers reluctant to
prescribe generic medicines (Al-Tamimi et al., 2013; Sharrad
et al., 2009) but also lose conﬁdence in the whole healthcare
system (Editorial-Lancet, 2012).
6.2. Generic medicine promotion programmes
As the healthcare systems are different from one country to an-
other and challenges and barriers to generic medicines might
also be different, it is important to have a comprehensive plan
and well-designed promotion programme that address, from
various perspectives, all aspects related to generic medicines.
This should include a plan for overcoming obstacles to
improving utilisation. The Japanese ‘‘Action Programme for
Promotion of the Safe Use of Generic Drugs’’ is a good
example of promotion programmes (MHLW, 2012a). More-
over, poorly managed programmes are in fact a barrier to
implementation of generic medicine policy (Kaplan et al.,
2012). In addition, it is evident that less comprehensive
educational campaigns may not fulﬁl the mission and short
programmes have minimal impact (Kobayashi et al., 2011a;
Simoens and De Coster, 2006).
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Quality use of generic medicines and successful implementa-
tion of generic substitution and generic prescribing require
communication and co-operation of all involved parties in this
process. There should be co-operation between healthcare pro-
fessionals (pharmacists, physicians and other prescribers and
dispensers). For example, when prescribers oppose GS by
community pharmacists, it is an obstacle to successful imple-
mentation of GS. Communication between the national regu-
latory authorities, healthcare professionals and consumers and
providing them with information about the requirements to
register medicines in general and generic medicines in particu-
lar is important. For example, in the US, the FDA, via the of-
ﬁce of generic drugs, provides valuable data about approved
generic medicines in the US with frequent updates on its web-
site so it can help healthcare professionals and consumers to
get the latest information about medicines registered in the
country. A further example, the National Prescribing Service
(NPS) in Australia plays a role in educating consumers about
generic medicines via educational campaigns and materials
about medicine brand choices.
6.4. Healthcare professionals: acceptance of generic medicines
Health care professionals play a pivotal role in the promotion
of cost effective use of medicines in general and generic medi-
cine in particular. Therefore, it is essential to address any con-
cerns that they have regarding the generic medicines such as
negative perceptions about quality, efﬁcacy and safety.
6.5. Patients: acceptance of generic medicines
Patients and drug consumers should be encouraged by health-
care professionals (pharmacists and physicians) to use generic
medicines. They should also be educated about generic medi-
cines by, for example, media and educational campaigns, be-
cause any concerns that patients have might make them
refuse GS, lead to confusion or affect their adherence to the
medicines. Moreover, it is evident in the literature that coun-
selling, advice and recommendations by healthcare profession-
als encourage patients to accept generic medicines and GS.
6.6. Evidence based references of therapeutically substitutable
medicines
To implement generic substitution and generic prescribing suc-
cessfully, it is important to have a guide on therapeutically
interchangeable drug products to help healthcare professionals
to perform GS appropriately and to avoid any pitfalls or errors
that may arise from inappropriate GS (Alrasheedy et al., 2013).
The orange book in the US, BNF in the UK, the Schedule of
PBS in Australia and the lists of interchangeable products in
Finland and Sweden are examples of such references.
6.7. Medicine prices and pricing systems
It is important not only to promote generic medicines but also
to evaluate prices of medicines and reasonability of their prices
and to ﬁnd mechanisms to reduce the prices of medicines. Thisis due to the fact that some medicines are priced more than ex-
pected in some countries (Cameron et al., 2009; WHO/HAI,
2006) and some generic medicines are even more expensive
than original brand medicines (Shaﬁe and Hassali, 2008). In
Australia, for example, mandatory price reduction and price
disclosure were intended to reduce the prices of medicines
and make sure the reimbursement reﬂects the actual prices.
Furthermore, the price difference was a determinant factor
for patients to accept generic medicines, because they refuse
GS when cost saving or price difference is minimal.
6.8. Reimbursement system and ﬁnancial incentives
The efforts to promote generic medicines should also consider
a reimbursement system and ﬁnancial incentives for pharma-
cists and physicians. For instance, the mandatory generic sub-
stitution policies in some European countries require
pharmacists to reimburse only for dispensing the cheaper or
close to the cheaper therapeutic equivalent generic medicines.
In addition, the patients who refuse GS or choose a more
expensive brand should pay the price difference. Moreover,
as in Japan, ﬁnancial incentives could be considered to encour-
age physicians and pharmacists to recommend generic medi-
cines to their patients.
7. Conclusion
Generic medicines can provide substantial savings to health-
care systems. However, there are many challenges in imple-
menting fully generic medicine policies to get the maximum
beneﬁts. As the challenges are different from one healthcare
system to another, a well-designed programme to promote
generic medicines should address ﬁrst the challenges based
on the local settings. Furthermore, it seems that any main pol-
icy to promote generic medicines needs to be supported by
some complementary policies to facilitate its implementation
or to overcome the barriers that may hinder its effective
implementation.
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